Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prexton

- PMLiVE

Lundbeck’s Steve Turley re-elected as EMG chair

And Actelion's Robin Bhattacherjee retains vice-chair position

- PMLiVE

GSK and Impax end Parkinson’s collaboration

Regulatory delays for IPX066 lead to split

Online Parkinson’s community launched

Britannia Pharmaceuticals' initiative focuses on mid- to late-stages of the disease

- PMLiVE

Lundbeck launches alcohol drug Selincro in Europe

Norway, Finland, Poland and the Baltic countries chosen as first markets

- PMLiVE

Otsuka licenses Lundbeck’s Alzheimer’s drug in $825m deal

Lu AE58054 is in phase III development as add-on to donepezil

- PMLiVE

Otsuka and Lundbeck extend CNS collaboration

Follows US approval of depot antipsychotic Abilify Maintena

- PMLiVE

Depot Abilify approval in US buoys Lundbeck and Otsuka

FDA licences the once-monthly version of Lundbeck's blockbuster schizophrenia drug

- PMLiVE

Lundbeck’s alcohol dependency drug approved in Europe

Selincro is the first drug approved to reduce alcohol consumption

- PMLiVE

Former Nycomed CEO Hakan Bjorklund to chair Lundbeck

Mats Pettersson to step down in March

- PMLiVE

Phytopharm shares dive as Parkinson’s drug fails

Stock falls 80 per cent after Cogane failure in phase II

- PMLiVE

Lundbeck looks to new products as Lexapro slumps

Denmark-based pharma company reports flat sales during fourth quarter of 2012

- PMLiVE

Lundbeck launches Chorea Matters online resource

Includes recognising chorea education programme

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links